Senator Mike Crapo @MikeCrapo
The Administration’s drug price-setting program poses serious risks for patients, frontline health care providers, small businesses, and American pharmaceutical innovation. I raised these important concerns and questions for federal health agencies: https://t.co/f1Q6pywpMU — PolitiTweet.org